ResearcherUniversity Medical Center Hamburg-EppendorfNo recent work listed
Bianca T. Hofmann
Matched on ORCID iD 0000-0003-1565-1319; OpenAlex author ID A5001884144. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 21
2014: 2 papers · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper
Papers 6
- Truncated O-GalNAc glycans impact on fundamental signaling pathways in pancreatic cancer. Co-author DOI 10.1093/glycob/cwab088↗
- Biperiden and mepazine effectively inhibit MALT1 activity and tumor growth in pancreatic cancer. Co-author DOI 10.1002/ijc.32567↗
- Inhibition of Six1 affects tumour invasion and the expression of cancer stem cell markers in pancreatic cancer. Co-author DOI 10.1186/s12885-017-3225-5↗
- COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer. Co-author DOI 10.1186/s12943-015-0386-1↗
- Pancreatic cancer. First author DOI 10.1111/bph.12401↗
- ABO blood group IgM isoagglutinins interact with tumor-associated O-glycan structures in pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-14-0716↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Gerrit Wolters‐Eisfeld · 5 shared papers, 2014–2021 · strength 0.33
- Maximilian Bockhorn · 5 shared papers, 2014–2021 · strength 0.33
- Cenap Güngör · 5 shared papers, 2014–2021 · strength 0.33
- Jakob Robert Izbicki · 4 shared papers, 2014–2021 · strength 0.27
- Paper Truncated O-GalNAc glycans impact on fundamental signaling pathways in pancreatic cancer. DOI 10.1093/glycob/cwab088↗
- Paper Biperiden and mepazine effectively inhibit MALT1 activity and tumor growth in pancreatic cancer. DOI 10.1002/ijc.32567↗
- Paper COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer. DOI 10.1186/s12943-015-0386-1↗
- Christoph Kahlert · 2 shared papers, 2017–2021 · strength 0.17
- Alexander T. El Gammal · 2 shared papers, 2015–2020 · strength 0.12
- Kai A. Bachmann · 1 shared paper, 2021 · strength 0.12
- Leonie Konczalla · 1 shared paper, 2020 · strength 0.08
- Udo Schumacher · 1 shared paper, 2020 · strength 0.08
- Faik Güntac Uzunoglu · 1 shared paper, 2020 · strength 0.08
- Georg Feldmann · 1 shared paper, 2017 · strength 0.06
- Nuh N. Rahbari · 1 shared paper, 2017 · strength 0.06
- Mathieu Pecqueux · 1 shared paper, 2017 · strength 0.06
- Tristan Lerbs · 1 shared paper, 2017 · strength 0.06
- Christoph Reißfelder · 1 shared paper, 2017 · strength 0.06
- Savita Bisht · 1 shared paper, 2017 · strength 0.06
- Sebastian Schölch · 1 shared paper, 2017 · strength 0.06
- Thilo Welsch · 1 shared paper, 2017 · strength 0.06
- Jürgen Weitz · 1 shared paper, 2017 · strength 0.06
- Florian Gebauer · 1 shared paper, 2014 · strength 0.04
- Michael Tachezy · 1 shared paper, 2014 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.